Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism after Cancer Remission

Figures

• 

  Fig. 1 Flowchart of participant inclusion.

• 

  Fig. 2 Kaplan–Meier curve of estimated composite incidence of all-cause death and major bleeding and recurrent venous thromboembolism between the cancer remission and continued cancer treatment groups. The event-free survival rate was 0.9% in the cancer remission group and 42.9% in the continued cancer treatment group.

• 

  Fig. 3 Kaplan–Meier curve of estimated composite incidence of all-cause death and recurrent venous thromboembolism and bleeding between the completion of anticoagulation and continued anticoagulation groups. The event-free survival rate was 98.9% in the completion of anticoagulation group and 87% in the continued anticoagulation group. The completion of anticoagulation group had a lower incidence of composite events (A). No significant differences were observed for recurrent VTE between the two groups (log rank, P=0.611); the recurrence rate of the completion of anticoagulation group was 1.1% (B).